Responses
Clinical/translational cancer immunotherapy
Original research
Phase II trial of efficacy, safety and biomarker analysis of sintilimab plus anlotinib for patients with recurrent or advanced endometrial cancer
Compose a Response to This Article
Other responses
No responses have been published for this article.
